Welcome to our dedicated page for Seer news (Ticker: SEER), a resource for investors and traders seeking the latest updates and insights on Seer stock.
Seer, Inc. develops and commercializes research-use proteomics products centered on its Proteograph Product Suite. The suite integrates proprietary engineered nanoparticles, optimized consumables, automation instrumentation and analytical software for proteomic analysis in research laboratories, academic institutions and biopharmaceutical settings.
SEER news commonly covers financial results and outlook, Proteograph adoption, research collaborations in multi-omic and population-scale studies, intellectual-property developments involving particle-based protein enrichment, and commercial leadership changes. Company updates also include governance and shareholder matters, including board responses to unsolicited proposals, director nominations, rights plans and other capital-structure actions.
Summary not available.
Summary not available.
Seer (Nasdaq: SEER) received an unsolicited, non-binding proposal from Chair and CEO Omid Farokhzad, M.D. to acquire all outstanding Class A common shares for $2.45 in cash per share plus two contingent value rights.
A Special Committee of independent directors will evaluate this proposal and other strategic alternatives with independent financial and legal advisors. No stockholder action is required now.
Summary not available.
Summary not available.
Summary not available.
Seer (Nasdaq: SEER) and Korea University reported preliminary ASMS 2026 data showing AI-driven analysis of deep plasma proteomics for potential multi-cancer screening.
The collaboration analyzed over 5,500 plasma samples across ten major cancer types, averaging 14,000 protein groups per sample, and targets more than 20,000 clinical samples overall.
Summary not available.
Summary not available.
Summary not available.